Discovery and preclinical development of novel regenerative-inducing peptide candidates
First written in FY2019. 15 of 22 entries say "Restated". Latest entry: 2026-10-06.
2 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「For TRIM3 and TRIM4, novel regenerative medicine candidate compounds following retasemtiv, the company steadily accumulated experimental data from disease-model animals and continued to make progress in business development activities aimed at out-licensing them.」
For TRIM3 and TRIM4, the accumulation of experimental data from animal models of diseases and business development activities aimed at licensing out the products are continuing. - 2026-03-11RestatedEarnings
「For TRIM3 and TRIM4, the second-generation in vivo regenerative medicine candidates following Redasemtide, preclinical development and business development activities toward out-licensing continued to progress.」
The continuation of preclinical development and business development activities toward out-licensing for TRIM3 and TRIM4 was reconfirmed, but no new specific milestone was disclosed. - FY2025AdvancedAnnual report
「For TRIM5, the local administration of the regeneration-inducing medicine to small damaged tissue sites and to sites where considerable time has passed since the injury is intended to mobilize mesenchymal stem cells more efficiently and promote repair of the tissue damage.」
Regarding discovery and preclinical development of novel candidates, the local-administration candidate TRIM5 and the mechanism and development policy aimed at concentrating stem cells at damaged sites have been specified. - FY2025-H1RestatedAnnual report
「For TRIM3 and TRIM4, novel regenerative medicine candidate compounds following retasemtiv, the company steadily accumulated experimental data from disease-model animals and continued to make progress in business development activities aimed at out-licensing them.」
For TRIM3 and TRIM4, activities to accumulate experimental data from animal models of diseases and pursue licensing-out opportunities are continuing, but no new specific milestone was presented compared with the previous description. - FY2024AdvancedAnnual report
「Next-generation regeneration-inducing medicines TRIM3 and TRIM4 increase mesenchymal stem cells in peripheral blood, like PJ1: Redasemtide, thereby inducing tissue regeneration for a broad range of diseases involving tissue injury. During the fiscal year, the Company steadily accumulated experimental data from animal models of each disease and continued to make progress in business development activities aimed at licensing out the products.」
For TRIM3 and TRIM4, progress was reported in accumulating experimental data from animal models of each disease and conducting business development activities aimed at licensing out the products. - FY2024-Q3RestatedAnnual report
「In its project to discover novel regenerative medicine candidate compounds other than retasemtiv, the company has continued active R&D investment to select next-generation development candidates and conducted multifaceted candidate-compound screening, ultimately identifying multiple novel candidate compounds with significant activity.」
The multifaceted screening of novel regeneration-inducing medicine candidates and identification of multiple candidate compounds were reconfirmed. - FY2024-Q1RestatedAnnual report
「In its project to discover novel regenerative medicine candidate compounds other than retasemtiv, the company has continued active R&D investment to select next-generation development candidates and conducted multifaceted candidate-compound screening, ultimately identifying multiple novel candidate compounds with significant activity.」
The multifaceted screening of novel regeneration-inducing medicine candidates and identification of multiple candidate compounds were reconfirmed. - FY2023AdvancedAnnual report
「TRIM3 and TRIM4, particularly promising peptides among these candidates, have been shown to improve symptoms in animal models of multiple tissue-injury diseases.」
The candidate names TRIM3 and TRIM4 were presented for next-generation novel regeneration-inducing medicine candidates, and symptom improvement was confirmed in multiple tissue-injury disease models. - FY2023-Q1RestatedAnnual report
「In its project to discover novel regenerative medicine candidate compounds other than retasemtiv, the company has continued active R&D investment to select next-generation development candidates and conducted multifaceted candidate-compound screening, ultimately identifying multiple novel candidate compounds with significant activity.」
The multifaceted screening of novel regeneration-inducing medicine candidates and identification of multiple candidate compounds were reconfirmed. - FY2022RestatedAnnual report
「The Company has more than 10 candidate peptides identified through screening to date and plans to develop them sequentially, starting with those offering the greatest therapeutic effects.」
The Company has more than 10 candidate peptides, and its policy of developing the candidates with the greatest therapeutic effects first was reconfirmed. - FY2022-Q1RestatedAnnual report
「In its project to discover novel regenerative medicine candidate compounds other than retasemtiv, the company has continued active R&D investment to select next-generation development candidates and conducted multifaceted candidate-compound screening, ultimately identifying multiple novel candidate compounds with significant activity.」
The multifaceted screening of novel regeneration-inducing medicine candidates and identification of multiple candidate compounds were reconfirmed. - FY2021AdvancedAnnual report
「Based on the basic research described above, we accumulated new knowledge about mesenchymal stem cells present in the body and developed RIM3, a novel synthetic peptide that mobilizes bone marrow mesenchymal stem cells into the bloodstream. RIM3 has been shown to improve symptoms in animal models of ulcerative colitis, atopic dermatitis and cerebral infarction.」
The synthetic peptide RIM3 was obtained as a novel candidate, and symptom improvement was confirmed in animal models of ulcerative colitis, atopic dermatitis and cerebral infarction. - FY2021-Q3RestatedAnnual report
「In its project to discover novel regenerative medicine candidate compounds other than retasemtiv, the company has continued active R&D investment to select next-generation development candidates and conducted multifaceted candidate screening, ultimately identifying multiple novel candidate compounds with significant activity.」
The multifaceted screening of novel regeneration-inducing medicine candidates and identification of multiple candidate compounds were reiterated. - FY2021-Q2RestatedAnnual report
「In its project to discover novel regenerative medicine candidate compounds other than retasemtiv, the company has continued active R&D investment to select next-generation development candidates and conducted multifaceted candidate screening, ultimately identifying multiple novel candidate compounds with significant activity.」
The multifaceted screening of novel regeneration-inducing medicine candidates and identification of multiple candidate compounds were reiterated. - FY2021-Q1RestatedAnnual report
「In its project to discover novel regenerative medicine candidate compounds other than the HMGB1 peptide, the company has continued active R&D investment to select next-generation development candidates and conducted multifaceted candidate screening, ultimately identifying multiple novel candidate compounds with significant activity.」
The explanation regarding the discovery of novel peptides and candidate substances and the identification of candidate compounds was reiterated. - FY2020-Q3RestatedAnnual report
「In its project to discover novel regenerative medicine candidate compounds other than the HMGB1 peptide, the company has continued active R&D investment to select next-generation development candidates and conducted multifaceted candidate screening, ultimately identifying multiple novel candidate compounds with significant activity.」
The multifaceted screening of novel regeneration-inducing medicine candidates and identification of multiple candidate compounds were reiterated. - FY2020-Q2RestatedAnnual report
「Through multifaceted screening of candidate substances, we have identified multiple novel candidate compounds with significant activity.」
The multifaceted screening of novel regeneration-inducing medicine candidates and identification of multiple candidate compounds were reiterated. - FY2020-Q1AdvancedAnnual report
「Through continued investment in research and development aimed at selecting next-generation development candidates and multifaceted screening of candidate substances, we have identified multiple new candidate compounds with significant activity.」
Specific progress was presented in the discovery of novel drug candidates, with multiple candidate compounds possessing significant activity identified. - FY2019First statedAnnual report
「The Company has more than 10 candidate peptides identified through screening to date and plans to develop them sequentially, starting with those offering the greatest therapeutic effects. At present, preclinical studies required before initiating clinical trials are being conducted on 3 candidate peptides.」
The Company has more than 10 candidate peptides and is conducting preclinical studies required before clinical trials for 3 candidates.